July 7, 2010

WALTHAM, Mass, July 7, 2010 -- Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for SBC-102, the Company’s enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease (CESD), a condition for which there is currently no approved treatment. As a result of the orphan drug designation, Synageva BioPharma will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, waiver of the FDA filing and registration fees, and seven years of market exclusivity upon approval. U.S. orphan drug designation is granted to a product that treats a rare disease, a condition that affects fewer than 200,000 Americans.

About Synageva BioPharma Corp.

Synageva BioPharma Corp. is dedicated to discovering, developing and commercializing therapies for patients with rare conditions and high unmet medical need. The Company has developed a pipeline of novel therapeutics for underserved populations and has assembled a team with a proven record of bringing orphan therapies to patients. Synageva BioPharma has the ability to use its proprietary protein expression technology (SEP™), which due to its flexibility, scalability and consistency of end product is uniquely suited for the development and commercialization of personalized medicines for patients with rare diseases. Further information regarding Synageva BioPharma Corp. is available at


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.